MediciNova names Yoshio Ishizaka to its board
M2 - Wed Apr 09, 6:02AM CDT
US-based biopharmaceutical company MediciNova (NASDAQ GM:MNOV) disclosed on Tuesday the addition of Yoshio Ishizaka to its board of directors.
MediciNova Announces Management Appointment
GlobeNewswire - Tue Apr 08, 6:00PM CDT
MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the appointment of Esther van den Boom as Chief Financial Officer.
MediciNova Appoints Yoshio Ishizaka to its Board of Directors
GlobeNewswire - Tue Apr 08, 6:00PM CDT
MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the appointment of Mr. Yoshio Ishizaka to its Board of Directors.
Treatments for Non-Alcoholic Steatohepatitis Making Clinical Strides
ACCESSWIRE - Tue Apr 08, 10:00AM CDT
WHITEFISH, MT / April 8, 2014 / There has been a disease steadily filling market headlines recently, and no; it's not cancer. It's fatty liver disease, particularly Non-alcoholic Fatty Liver Disease, or NAFLD, regarded by many as the most common non-communicable liver disease worldwide. The disease is a silent killer that often goes undetected until late stages, for which there are no FDA-approved treatments. Biotechs focusing on innovative therapies for varying stages of NAFLD are receiving plenty of deserved media coverage. Hepatology leaders in recent headlines include Intercept Pharmaceuticals, (NASDAQ: ICPT), Cempra, Inc. (NASDAQ: CEMP), MediciNova, Inc. (NASDAQ: MNOV), Galectin Therapeutics (NASDAQ: GALT) and Lumena Pharmaceuticals, a company preparing to go public.
Canadian Forex Review: C$ Lower Ahead of BoC Announcement
Commodity News Service Canada - Commodity News Service Canada, Inc. - Tue Mar 04, 3:46PM CST
The Canadian dollar closed lower on Tuesday, undermined by positioning ahead of Wednesday's Bank of Canada policy announcement, analysts said.
Five Worst, Pandering Drug Stocks of J.P. Morgan Healthcare Confab Week
at The Street - Fri Jan 17, 2:52PM CST
The drug companies on this list issued the most ridiculous, stock-touting press releases, all seeking to glom onto the excitement of the JPM healthcare conference.
Nasdaq stocks posting largest volume increases
AP - Wed Jan 15, 5:06PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
MediciNova Announces Positive Results in NASH Mouse Model With MN-001 and Prepares to Initiate Phase 2 Trial in the U.S.
GlobeNewswire - Tue Jan 14, 7:00AM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive results from a study that examined the potential clinical efficacy of MN-001 for the treatment of NASH (nonalcoholic steatohepatitis).
MediciNova (MNOV) Jumps: Stock Adds 22.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 13, 6:51AM CST
MediciNova Inc. was a big mover last session, as its shares rose over 22% on the day.
MediciNova Inc wins new patent for MN-221 for irritable bowel syndrome
M2 - Tue Nov 12, 8:07AM CST
Biopharmaceutical company MediciNova Inc (NASDAQ GM:MNOV) on Monday reported the receipt of the new US patent for MN-221 for the treatment of irritable bowel syndrome.
MediciNova Inc to launch clinical trial of MN-166 (ibudilast) for alcohol dependence, with funding from NIAAA
M2 - Mon Aug 26, 10:43AM CDT
Biopharmaceutical company MediciNova Inc (NASDAQ GM:MNOV) said on Sunday that its clinical trial of MN-166 (ibudilast) for alcohol dependence will be funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health.
National Institute on Alcohol Abuse and Alcoholism Funds New UCLA Clinical Trial of MediciNova's MN-166 in Treating Alcoholism
GlobeNewswire - Sun Aug 25, 6:00PM CDT
The University of California, Los Angeles' (UCLA's) Departments of Psychology, and Psychiatry and Biobehavioral Sciences Brain Research Institute, and MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced that the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health, will fund a clinical trial of MN-166 (ibudilast) for alcohol dependence. The proposed trial has also completed FDA review. MediciNova previously announced an ongoing Phase 2a trial of MN-166 in opioid dependence with Columbia University investigators, and a UCLA Phase 2b trial in methamphetamine dependence anticipated to initiate enrollment later this quarter - both funded by the National Institutes of Drug Abuse (NIDA).
MediciNova Inc posts higher net loss of USD2.8m for Q2 2013
M2 - Fri Aug 09, 4:13AM CDT
Biopharmaceutical company MediciNova Inc (NASDAQ GM:MNOV) stated on Thursday its net loss of USD2.8m (USD0.14 per share) for the second quarter ended 30 June 2013.
MediciNova Reports Second Quarter 2013 Results
GlobeNewswire - Thu Aug 08, 4:30PM CDT
MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the second quarter ended June 30, 2013 through the filing of its quarterly report on Form 10-Q.
ATSG, NOA, MNOV, USAT, GLUU, OPTT Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Fri Jul 19, 5:09AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Air Transport Services Group Inc (NASDAQ:ATSG), North American Energy Partners Inc (NYSE:NOA), MediciNova Inc (NASDAQ:MNOV), USA Technologies Inc (NASDAQ:USAT), Glu Mobile Inc (NASDAQ:GLUU), Ocean Power Technologies Inc (NASDAQ:OPTT) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
MediciNova Announces Initiation of a Cooperative Phase 2b Trial of MN-166 in Progressive Multiple Sclerosis
GlobeNewswire - Thu Jul 18, 6:00PM CDT
MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the funding and regulatory approvals of a NIH-based grant for a Phase 2b trial of MN-166 (ibudilast) in subjects with progressive multiple sclerosis (progressive MS). The principal investigator will be Robert Fox, M.D., M.S., FAAN, Staff Neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic.
Market Maker Surveillance Report. ASYS, ARL, LEE, MNOV, OXBT, ICPT, Winning Stocks With Lowest Price Friction For Wednesday, June 19th 2013
M2 - Thu Jun 20, 3:08AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 3792 companies with "abnormal" market making, 1479 companies with positive Friction Factors and 3882 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Wednesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Amtech Systems Inc (NASDAQ:ASYS), American Realty Investors Inc (NYSE:ARL), Lee Enterprises Inc (NYSE:LEE), MediciNova Inc (NASDAQ:MNOV), Oxygen Biotherapeutics Inc (NASDAQ:OXBT), (NASDAQ:ICPT). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices
MediciNova Presents MN-166 Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 19, 4:15PM CDT
MediciNova announced the presentation of preliminary data from a phase Ib study of MN-166 for the treatment of methamphetamine addiction